In an interview with the ABC's AM program, the co-chair of the Australian Technical Advisory Group on Immunisation (ATAGI), associate professor Christopher Blyth, said it should only be considered in "pressing" circumstances.
"There are some situations where that would be warranted, but they are quite small," he said.
"The ATAGI advice is that Pfizer is our preference for those under the age of 60 years."
